21ENGBIO-THE TRANSDUCING ANALYTICAL BIOSYSTEM (TABS): A PLATFORM FOR DIAGNOSTICS (TABS-DX)

21ENGBIO-转换分析生物系统 (TABS)：诊断平台 (TABS-DX)

• 批准号: BB/W011905/1
• 负责人: Elizabeth Hall
• 金额: $ 12.83万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FW011905%2F1
• 关键词: 21ENGBIO; TRANSDUCING; ANALYTICAL; BIOSYSTEM; TABS

The world market for biosensors was $42Bn before Covid and is expected to double in the next 6yrs, still dominated by clinical diagnostics and disease management, demanding new technologies for early detection at lower cost. Covid-19 testing made in vitro diagnostics (IVDs) a household product, but IVDs are not only expected to play their part in faster identification of causative pathogens and containment of infectious disease, but there is also a need in treatment and management in acute and chronic disease, enabling earlier diagnosis with appropriate treatment, improving patient outcomes. There is interest from neonatal and paediatric units in Cystatin C (CysC) as a marker of acute renal function, as well as a predictor of morbidity and mortality. It is a much earlier indicator than the normally used creatinine and is particularly attractive for assessing kidney function in paediatrics/neonatology and intensive care, where acute fluctuations in glomerular filtration rate GFR and lack of creatinine sensitivity to incipient renal impairment puts children at risk from antibiotic toxicity. Many bioanalytical reagents for medical diagnostics are enzymes, antibodies, peptides etc. They are derived from nature and mostly produced by fermentation techniques. However, they aren't intrinsically smart materials; ie they don't usually yield an analytical signal that can be measured without further (chemical) modification of the bioanalytical reagent or addition of chemical indicators. The additional manufacturing costs and chemical reagents adds significant cost and reduces the 'green' impact of the manufacturing by fermentation. It also means that small volume biomarker measurement targets do not become commercially viable. It needs 'blockbuster' targets like glucose monitoring for diabetics to be an attractive commercial investment.In this project we will use synthetic biology to make smart analytical reagents: the TRANSDUCING ANALYTICAL BIOSYSTEM (TABS) as a platform for diagnostics (TABS-DX). The TABS can be attached to fibres and particles, making them easier to use and to store. A CysC point of care test system will be designed and a novel vacuum printing technique will be trialed to deposit the fibres or particles to produce prototype in vitro diagnostics for CysC, which will be tested in a clinical study, with the paediatrics unit.

世界生物传感器的世界市场在COVID之前为420亿美元，预计在接下来的6年中将增加一倍，但仍由临床诊断和疾病管理主导，要求以较低的成本进行早期检测的新技术。 COVID-19进行体外诊断（IVD）的测试是家用产品，但IVD不仅预计将在更快地识别病原体和传染病的抑制速度中发挥作用，而且在急性和管理方面也需要急需慢性疾病，可以通过适当的治疗来早期诊断，改善患者的结局。新生儿和小儿单位对抑制蛋白C（CYSC）的兴趣是急性肾功能的标志，以及发病率和死亡率的预测指标。它比通常使用的肌酐要早得多，对于评估儿科/新生儿学和重症监护的肾脏功能特别有吸引力，在该功能中，肾小球过滤率GFR的急性波动GFR以及缺乏肌酐对初期肾脏损害的敏感性使儿童受到抗生素的风险。毒性。许多用于医学诊断的生物分析试剂是酶，抗体，肽等。它们源自自然，主要由发酵技术产生。但是，它们不是本质上智能的材料。即它们通常不会产生分析信号，该信号无需对生物分析试剂的进一步修改或化学指标的添加而进行测量。额外的制造成本和化学试剂增加了大量成本，并通过发酵来减少制造业的“绿色”影响。这也意味着少量的生物标志物测量目标在商业上不可行。它需要诸如糖尿病患者的葡萄糖监测之类的“大片”目标是有吸引力的商业投资。在该项目中，我们将使用合成生物学来制作智能分析试剂：转导分析生物系统（TABS）作为诊断平台（TABS-DX）。选项卡可以连接到纤维和颗粒上，使其更易于使用和存储。将设计一个CYSC护理测试系统，并将试用一种新颖的真空打印技术来沉积纤维或颗粒，以在CYSC的体外诊断中产生原型，该诊断将在一项临床研究中对儿科单元进行测试。